Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry
Stephan Grupp, et al.
In the real-world, tisa-cel has similar efficacy and improved safety in pediatric ALL patients. OOS product (viability 60-80%) does not impact efficacy
Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
Andrea Kuhnl, et al.
In this study, 122 patients were treated with axicabtagene ciloleucel and tisagenlecleucel. Details on bridging therapy, treatment-related toxicities and outcomes will be provided at the meeting, by which time 62 patients will have completed their 3 months PET response assessment
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Samantha Jaglowski, et al.
In the real-world, tisa-cel has similar efficacy and improved safety in DLBCL patients. OOS product (viability 60-80%) does not impact efficacy
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Samantha Jaglowski, et al.
In the real-world, tisa-cel has similar efficacy and improved safety in DLBCL patients. OOS product (viability 60-80%) does not impact efficacy
Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
Jakub Svoboda, et al.
Three-month complete response rates are considered reasonably predictive of outcome for CART19 therapies. Bendamustine as LDC for tisa-cel performs well outside of a clinical trial, is an option for LDC before tisa-cel therapy for pts with r/r aggressive B-cell lymphomas treated in the outpatient setting, and may have an improved safety profile with regard to cytopenias